Docality.com Logo
 
Dr. Joshua  Pond  Dc image

Dr. Joshua Pond Dc

2049 Glenns Bay Rd Suite 105
Surfside Beach SC 29575
843 500-0247
Medical School: Other - Unknown
Accepts Medicare: No
Participates In eRX: No
Participates In PQRS: No
Participates In EHR: No
License #: 2894
NPI: 1063569309
Taxonomy Codes:
111N00000X

Request Appointment Information

Awards & Recognitions

About Us

Practice Philosophy

Conditions

Medical Malpractice Cases

None Found

Medical Board Sanctions

None Found

Referrals

None Found

Publications

Translating clinical trials to clinical practice: outcomes of men with metastatic castration resistant prostate cancer treated with docetaxel and prednisone in and out of clinical trials. - Annals of oncology : official journal of the European Society for Medical Oncology / ESMO
Multiple factors can influence outcomes of patients receiving identical interventions in clinical trials and in routine practice. Here, we compare outcomes of men with metastatic castrate-resistant prostate cancer (mCRPC) treated with docetaxel and prednisone in routine practice and in clinical trials.We reviewed patients with mCRPC treated with docetaxel at Princess Margaret Cancer Centre. Primary outcomes were overall survival and PSA response rate. Secondary outcomes were reasons for discontinuation and febrile neutropenia. Outcomes were compared for men treated in routine practice and in clinical trials, and with data from the TAX 327 study.From 2001 to 2011, 438 men were treated, of whom 357 received 3-weekly docetaxel as first-line chemotherapy: 314 in routine practice and 43 in clinical trials. Trial patients were younger and had better performance status. Median survival was 13.6 months [95% confidence interval (95% CI) 12.1-15.1 months] in routine practice and 20.4 months (95% CI 17.4-23.4 months, P = 0.007) within clinical trials, compared with 19.3 months (95% CI 17.6-21.3 months, P < 0.001) in the TAX 327 study. PSA response rates were 45%, 54%, and 53%, respectively (P = NS). Reasons for treatment discontinuation were similar although trial patients received more cycles (median: 6 versus 8 versus 9.5, P < 0.001). Rates of febrile neutropenia were 9.6, 0, and 3% (P < 0.001) while rates of death within 30 days of last dose were 4%, 0%, and 3%, respectively (P = NS).Survival of patients with mCRPC treated with docetaxel in routine practice is shorter than for men included in trials and is associated with more toxicity.
Influence of concurrent medications on outcomes of men with prostate cancer included in the TAX 327 study. - Canadian Urological Association journal = Journal de l'Association des urologues du Canada
The TAX 327 trial was pivotal in establishing docetaxel in castration refractory metastatic prostate cancer. Various commonly prescribed and over-the-counter co-administered medications are thought to exhibit anti-neoplastic properties and/or could potentially have pharmacokinectic interactions with docetaxel lessening the effectiveness of chemotherapy.To examine the effect of on prostate cancer outcomes within this trial, we examined overall survival, prostate-specific antigen (PSA) response, percent PSA reduction, pain response and QOL responses for 14 families of medications including metformin, digoxin, verapamil, proton pump inhibitors, nitrates, statins, cox-2 inhibitors, warfarin, heparins, ascorbic acid, selenium, tocopherol, antidepressants and erythropoietin.Our findings did not reveal any medication that had a significant additive or synergistic effect with docetaxel. We did note, however, that patients on digoxin or verapamil had poorer overall survival, possibly due to a trend of fewer cycles of administered chemotherapy being administered to the verapamil group, consistent with a pharmacokinectic interaction.These data are only hypothesis-generating given the statistical limitations, but may form a basis for similar future analysis in other malignancies. The data suggest the need to be aware of pharmacokinectic interactions with medications that may interact with docetaxel.

Map & Directions

2049 Glenns Bay Rd Suite 105 Surfside Beach, SC 29575
View Directions In Google Maps

Nearby Doctors

1120 Glenns Bay Rd Suite 101
Surfside Beach, SC 29575
843 155-5492
2751 Beaver Run Blvd. Box 8
Surfside Beach, SC 29575
843 158-8200
1625 Glenns Bay Rd
Surfside Beach, SC 29575
843 505-5100
640 E Hwy 17 S
Surfside Beach, SC 29575
843 381-1203
1413 Highway 17 N
Surfside Beach, SC 29575
843 385-5654
1625 Glenns Bay Rd
Surfside Beach, SC 29575
843 505-5100
1943 Glenns Bay Rd
Myrtle Beach, SC 29575
843 501-1162
1616 Azalea Dr
Surfside Beach, SC 29575
843 385-5111
400 Highway 17 N Suite A
Surfside Beach, SC 29575
843 385-5900